New GLAAS System Results Shown At AAAI Meeting

The American Academy of Allergy, Asthma and Immunology held its annual meeting in Los Angeles, California and the 2016 meeting included a presentation from Immune Design to present data on its GLAAS platform. The data highlighted the ability to use GLA for both pollen-based allergy treatments and peanut allergy treatments.

The AAAI meeting's presentation showed that the synthetic molecule GLA (glucopyranosyl lipid adjuvant) will bind with receptors that cause activation of the allergic immune response called the Th1-type response. Using an antigen added to the GLA, injections can potentially reduce allergic responses by blocking these "allergy receptors."

Originally developed for cancer treatment.

GLAAS was originally developed as a cancer treatment, research for which is ongoing. Immune Design is now broadening the use of GLAAS into allergy treatments by targeting pollen and peanut allergies with the method.

"These presentations add to the large and growing body of data supporting the potential of the GLAAS platform for the treatment of chronic diseases beyond cancer, where Immune Design is focused, including allergy,” said Jan ter Meulen, MD, PhD, Chief Scientific Officer at Immune Design.

The company plans to continue testing and further trials of the protocols for allergy treatments.

Source: GlobeNewsWire

Peanut Free Store

More Articles

Are you looking for peanut-free candies as a special treat for a child with...

Do you have a child with peanut allergies and an upcoming birthday? Perhaps you'd like to bake a...

Most nut butters provide all the same benefits: an easy sandwich spread, a great dip for veggies, a fun addition to a smoothie. But not...

Do you have a sweet tooth and more specifically a chocolate craving? Those with peanut allergies must...

You already know that if you or your child has a peanut allergy you need to avoid peanut butter. Some...

Top Forum Categories

Click on one of the categories below to see all topics and discussions.